ASCO Annual Meeting | Conference

Atezolizumab Plus Chemo Extends PFS in Frontline Squamous NSCLC

June 2nd 2018

The addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) delayed the risk of progression or death by 29% compared with chemotherapy alone for patients with advanced squamous NSCLC.

LOXO-292 Shows Impressive Response Rates for RET-Positive Tumors

June 2nd 2018

The highly-selective RET inhibitor LOXO-292 demonstrated robust clinical activity across RET-altered solid tumors, including in patients with brain metastases and the RET V804M gatekeeper mutation.

Ibrutinib/Rituximab Reduces Progression Risk by 80% in Waldenstrom Macroglobulinemia

June 2nd 2018

Adding ibrutinib to rituximab lowered the risk of disease progression or death by 80% versus rituximab alone in patients with Waldenström macroglobulinemia.

bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma

June 2nd 2018

bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.

Dr. Mohile on Using a Geriatric Assessment in Older Patients With Cancer

June 2nd 2018

Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses pooled findings with a geriatric assessment for older patients with cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.

Dr. George on Results of Abi Race Trial in Prostate Cancer

June 2nd 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.

Pomalidomide Triplet Extends PFS in Relapsed/Refractory Myeloma

June 2nd 2018

Adding pomalidomide (Pomalyst) to bortezomib (Velcade) and low-dose dexamethasone reduced the risk of disease progression or death by 39% in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide.

Venetoclax/Carfilzomib Combo Highly Effective for t(11;14) Myeloma

June 2nd 2018

The addition of venetoclax to carfilzomib and dexamethasone demonstrated a 100% objective response rate with a very good partial response or better rate of 86% for patients with relapsed/refractory t(11;14) multiple myeloma.

Colorectal Cancer Treatment Twice as Costly in US Than Canada, Despite Similar Outcomes

June 2nd 2018

A study that compared costs of treatment for metastatic colorectal cancer in Western Washington and the province of British Columbia in Canada found that prices were more than twice as high for the US patients than for their Canadian counterparts, with no significant difference in outcomes.

Geriatric Assessment Improves Patient Satisfaction, Patient-Oncologist Communication

June 2nd 2018

Evaluating health-related concerns as part of routine care for elderly patients with advanced cancer significantly improved doctor-patient communication and patient satisfaction.

Black Men May Fare Better Than White Men With Standard mCRPC Therapy

June 2nd 2018

Black men with metastatic castration-resistant prostate cancer may experience greater benefits from chemotherapy and hormone-targeting treatment than their white counterparts.

Compared With Men, Women With Head and Neck Cancer Undertreated

June 1st 2018

Women with head and neck cancer may be severely undertreated and have higher death rates compared with their male counterparts.

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30th 2018

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

NGS Established as Most Cost-Effective Genetic Test for Metastatic NSCLC

May 17th 2018

Next-generation sequencing in metastatic non-small cell lung cancer can save Center for Medicare and Medicaid Services payers $1.4 million to $2.1 million.

Symptom Tracking System Reduces Severity in Patients With Head and Neck Cancer

May 17th 2018

Patients who used mobile and sensor technology to track their symptoms demonstrated reduced severity of their symptoms compared with patients who received standard care.

Despite USPSTF Recommendations and Medicaid Coverage, Data Show Low Lung Cancer Screening Rate

May 17th 2018

A total 1.9% of more than 7.6 million current and former heavy smokers in the United States underwent lung cancer screening in 2016, suggesting that it remains inadequate despite USPTF recommendations.

Shorter Trastuzumab Duration Matches 12-Month Standard for Early HER2+ Breast Cancer

May 17th 2018

A shorter 6-month course of adjuvant trastuzumab (Herceptin) was found to be noninferior for disease-free survival compared with the standard 12-month schedule for patients with HER2-positive early breast cancer.

Nelarabine Boosts 4-Year DFS Above 90% in Pediatric/AYA T-Cell Cancers

May 17th 2018

Adding nelarabine to escalating-dose methotrexate induced a 4-year disease-free survival rate of 91% in a cohort of pediatric and young adult patients with newly diagnosed T-cell cancers.

Cognitive Behavior Therapy, Acupuncture Improve Insomnia Symptoms in Cancer Survivors

May 17th 2018

Both cognitive behavior therapy for insomnia (CBT-I) and acupuncture produced clinically meaningful improvements in insomnia severity scores for cancer survivors, but data from the randomized CHOICE clinical trial showed that CBT-I was more effective overall for reducing the severity of insomnia.

Dr. Andorsky on the MAGNIFY Trial in Follicular Lymphoma

August 3rd 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.